NanoRepro AGXTER:NN6 +12.79%51 OCF Yield % is 7.83 as of Jul. 05, 2026. GuruFocus rates XTER:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 77.67% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for NanoRepro AG's OCF Yield % or its related term are showing as below:
XTER:NN6'
s OCF Yield % Range Over the Past 10 Years
Min: -60.7 Med: -2.71 Max: 61.55
Current: 7.83
During the past 13 years, the highest OCF Yield % of NanoRepro AG was 61.55%. The lowest was -60.70%. And the median was -2.71%.
XTER:NN6's OCF Yield % is ranked better than 77.67% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.99
vs XTER:NN6: 7.83
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
NanoRepro AG OCF Yield % Related Terms
NanoRepro AG OCF Yield % Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: OCF Yield % Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's OCF Yield % distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (XTER:NN6) has a OCF Yield % of 7.83 as of Jul. 05, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #48 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 22.3%.
Is NanoRepro AG's OCF Yield % too high?
NanoRepro AG's current OCF Yield % is 7.83. The Medical Diagnostics & Research industry median OCF Yield % is 0.99. NanoRepro AG's value of 7.83 is 690.9% above this industry median. Based on the distribution chart, NanoRepro AG ranks #48 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #48 out of 215 companies for OCF Yield %. This places NanoRepro AG in the top 22% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 0.99. NanoRepro AG's value of 7.83 is 690.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 0.99, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current OCF Yield % of 7.83 is 690.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current OCF Yield % is 7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.00, compared to a current price of €2.16 — trading 116% above its estimated fair value. The current OCF Yield % is 7.83 and 690.9% above the Medical Diagnostics & Research industry median of 0.99. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current OCF Yield % is 7.83 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.16 is trading 116% above its estimated GF Value™ of €1.00.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
OCF Yield %: 7.83
GF Value™: €1.00 vs. price of €2.16 (116% above fair value)
Industry Position: 690.9% above the Medical Diagnostics & Research median (#48 of 215)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for XTER:NN6
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
